Clinical Pharmacokinetics

, Volume 9, Issue 2, pp 136–156 | Cite as

Clinical Pharmacokinetics of Amiodarone

  • Roberto Latini
  • Gianni Tognoni
  • Robert E. Kates
Review Article

Summary

Amiodarone is an iodinated benzofuran derivative with recognised antiarrhythmic activity in man. As yet, its pharmacokinetic behaviour has not been satisfactorily characterised. Specific and sensitive high-pressure liquid Chromatographic methods have become available only recently and this partly explains the scarcity of pharmacokinetic data on the drug.

Available evidence suggests that absorption of amiodarone following oral administration is erratic and unpredictable; oral bioavailability ranges from 22 to 86%. The drug is eliminated largely by metabolism; less than 1% of the dose is excreted unchanged in the urine. Biliary excretion may have a role in the overall elimination of the drug. Desethylamiodarone is the only metabolite positively identified in the plasma of patients receiving treatment with amiodarone; no data are available on its possible pharmacological activity.

Since it is a highly lipophilic drug, amiodarone is extensively distributed into tissues. Adipose tissue and skeletal muscle accumulate large amounts of the drug during long term treatment. Myocardium/plasma ratios of amiodarone are high both in man and in animals; peak concentrations in the myocardium are reached within half an hour after administration of an intravenous bolus to dogs. Placental transfer of amiodarone has been demonstrated in humans, while its blood profile is not modified by dialysis treatment. In vitro protein binding of amiodarone has been reported to be 96.3 ± 0.6%.

The plasma half-life of amiodarone after single-dose administration has been reported to be in the range of 3.2 to 79.7 hours. However, after withdrawal of long term amiodarone treatment the half-life is as long as 100 days. Total body clearance ranges from 0.10 to 0.77 L/min after single-dose intravenous administration, and the apparent volume of distribution ranges between 0.9 and 148 L/kg.

Amiodarone disposition kinetics in patients with cardiac arrhythmias are not different from those in healthy volunteers. However, the possible effects of liver and cardiac failure on the drug’s kinetics have not been studied.

Amiodarone potentiates the anticoagulant effect of warfarin, probably by inhibition of its metabolism. Increases of steady-state concentrations of digoxin, together with the appearance of signs of digitalis toxicity, have been reported when amiodarone was given to patients receiving long term treatment with digoxin. Amiodarone has also been shown to interact with other antiarrhythmic agents such as quinidine and procainamide.

The time of onset of action of amiodarone after a single intravenous dose ranges between 1 and 30 minutes and its duration of effect between 1 and 3 hours. During long term oral treatment, the therapeutic effect is observed after a delay of 2 to 21 days and can last more than 1 month after withdrawal of therapy. The time course of amiodarone electrophysiological effects after intravenous bolus administration to dogs follows its myocardial concentrations.

The plasma steady-state concentration of amiodarone found to be effective in man ranges from 0.4 to 11.99 μg/ml; however, even if no therapeutic range has yet been defined, there is good agreement on keeping steady-state levels between 1.0 and 2.5 μg/ml in patients treated for arrhythmias.

Clinically relevant extracardiac side effects have been reported, such as corneal deposits, thyroid dysfunction, peripheral neuropathy, pulmonary fibrosis and, less importantly, liver toxicity. Many of these side effects seem related to the dose and duration of amiodarone therapy, but information on their relationship to drug plasma concentrations is not available.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Achilli, A.; Giacci, M.; Capezzuto, A.; DeLuca, F.; Guerra, R. and Serra, N.: Interazione digossina-chinidina e digossina-amiodarone. Effetti sulla concentrazione ematica del glucoside cardioattivo. Giomale Italiano di Cardiologia 11: 918–925 (1981).Google Scholar
  2. Adams, P.C.; Nicholson, M.R.; Storey, G.C.A.; Holt, D.W. and Campbell, R.W.F.: Amiodarone tissue distribution: Relation to adverse effects. British Heart Journal 43: 297 March (1983).Google Scholar
  3. Anastasiou-Nana, M.; Levis, G.M. and Moulopoulos, S.: Pharmacokinetics of amiodarone after intravenous and oral administration. International Journal of Clinical Pharmacology, Therapy and Toxicology 20: 524–529 (1982).Google Scholar
  4. Andreasen, F.; Agerbaek, H.; Bjerregaard, P. and Gøtzsche, H.: Pharmacokinetics of amiodarone after intravenous and oral administration. European Journal of Clinical Pharmacology 19: 293–299 (1981).PubMedCrossRefGoogle Scholar
  5. Beck-Peccoz, P.; Volpi, A.; Maggioni, A.P.; Cattaneo, M.G.; Piscitelli, G.; Giani, P.; Landolina, M.; Tognoni, G. and Faglia, G.: Further evidence that the effects of amiodarone are mediated in part by an inhibition of the metabolic action of thyroid hormones (Submitted for publication, 1983).Google Scholar
  6. Bockhardt, H.; Drenckhahn, D. and Lüllmann-Rauch, R.: Amiodarone-induced lipidosis-like alterations in ocular tissues of rats. Albrecht Von Graefes Archiv für Klinische und Experimentelle Ophthalmologie 207: 91–96 (1978).PubMedCrossRefGoogle Scholar
  7. Bonati, M.; D’Aranno, E.; Galletti, F.; Fortunati, M.T. and Tognoni, G.: Acute overdosage of amiodarone in suicidal attempt. Journal of Toxicology — Clinical Toxicology 20: 181–186 (1983b).PubMedCrossRefGoogle Scholar
  8. Bonati, M.; Galletti, F.; Volpi, A.; Cumetti, C.; Rumolo, R. and Tognoni, G.: Amiodarone in patients on long-term dialysis. New England Journal of Medicine 308: 906 (1983c).PubMedGoogle Scholar
  9. Bonati, M.; Gaspari, F.; Benfenati, E.; Neyroz, P.; Fabbri, E.; D’Aranno, V.; Galletti, F. and Tognoni, G.: Physicochemical and analytical characteristics of amiodarone. Journal of Pharmaceutical Sciences (In press, 1983a).Google Scholar
  10. Boppana, V.K.; Greenspan, A.; Swanson, B.N.; Spielman, S.; Ferguson, R.K.; Belhassen, B. and Rotmensch, H.H.: Clinical efficacy and serum concentrations of amiodarone. Clinical Pharmacology and Therapeutics 33(2): A23 (1983).Google Scholar
  11. Broekhuysen, J.; Laruel, R. and Sion, R.: Recherches dans Ia série des benzofurannes. XXXVII. Étude comparée du transit et du métabolisme de l’amiodarone chez diverses espèces animales et chez l’homme. Archives Internationales de Pharmacodynamie et de Therapie 177: 340–359 (1969).PubMedGoogle Scholar
  12. Cabasson, J.; Puech, P.; Mellet, J.M.; Guimond, C.; Bachy, C. and Sassine, A.: Analyse des effets électrophysiologiques de l’amiodarone par l’enregistrement simultané des potentiels d’action monophasiques et du faisceau de His. Archives des Maladies du Coeur et des Vaisseaux 69: 691–699 (1976).PubMedGoogle Scholar
  13. Candelpergher, G.; Buchberger, R.; Suzzi, G.L. and Padrini, R.: Passaggio trans-placentare dell’amiodarone: Evidenza elettrocardiografica e documentazione. Giornale Italiano di Cardiologia 12: 79–82 (1982).PubMedGoogle Scholar
  14. Charlier, R.; Deltour, G.; Baudine, A. and Chaillet, F.: Pharmacology of amiodarone, an anti-anginal drug with a new biological profile. Arzneimittel-Forschung 18: 1408–1417 (1968).PubMedGoogle Scholar
  15. Coumel, P. and Fidelle, J.: Amiodarone in the treatment of cardiac arrhythmias in children: One hundred thirty-five cases. American Heart Journal 100: 1063–1069 (1980).PubMedCrossRefGoogle Scholar
  16. Coutte, R.; Fontaine, G.; Frank, R.; Dragodanne, C.; Phan-Thuc, H. and Facquet, J.: Étude électrocardiologique des effets de l’amiodarone sur 1a conduction intracardiaque chez l’homme. Annales de Cardiologie et d’Angéiologie 25: 543–548 (1976).PubMedGoogle Scholar
  17. Debbas, N.M.G.; du Cailar, G; Sassine, A.; Derancourt, J.; Demaille, J.G. and Puech, P.: Determination of cardiac and plasma drug levels during long-term amiodarone therapy. European Journal of Clinical Investigation 13: 123–127 (1983a).PubMedCrossRefGoogle Scholar
  18. Debbas, N.M.G.; Bexton, R.S.; du Cailar, C.; Puech, P. and Camm, A.J.: Relation between myocardial amiodarone concentration and QT interval. British Heart Journal 49(No. 3): March 1983b).Google Scholar
  19. Facquet, J.; Nivet, M.; Alhomme, P.; Raharison, S. and Grosgogeat, Y.: Traitement de l’angine de poitrine par l’amiodarone. Presse Medicale 77: 725–726 (1969).PubMedGoogle Scholar
  20. Flanagan, R.J.; Storey, G.C.A. and Holt, D.W.: Rapid high-performance liquid Chromatographic method for the measurement of amiodarone in blood plasma or serum at the concentrations attained during therapy. Journal of Chromatography 187: 391–398 (1980).PubMedCrossRefGoogle Scholar
  21. Flanagan, R.J.; Storey, G.C.A.; Holt, D.W. and Farmer, P.B.: Identification and measurement of desethylamiodarone in blood plasma specimens from amiodarone-treated patients. Journal of Pharmacy and Pharmacology 34: 638–643 (1982).PubMedCrossRefGoogle Scholar
  22. Furlanello, F.; Inama, G.; Ferrari, M.; Padrini, R.; Guarnerio, M.; Vergara, G.; DalForno, P.; Bettini, R. and Disertori, M.: Un altro tipo di interazione fra livelli ematici della digitale e di farmaci antiaritmici: Digoxina ed amiodarone. Giornale Italiano di Cardiologia 11: 1725–1728 (1981).PubMedGoogle Scholar
  23. Giani, P.; Maggioni, A.P.; Volpi, A.; Martinelli, U.; Neyroz, P.; Riva, E. and Latini, R.: Significance of amiodarone blood level monitoring in the acute treatment of hyperkinetic arrhythmias. 5th International Seminar in Cardiology, pp. 68–69 (abstract) Trento, Italy (1982).Google Scholar
  24. Haffajee, C.I.; Love, J.C.; Canada, A.T.; Lesko, L.J.; Asdourian, G. and Alpert, J.S.: Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias. Circulation 67(6): 1347–1355 (1983).PubMedCrossRefGoogle Scholar
  25. Hamer, A.; Peter, T.; Mandel, W.J.; Scheinman, M.M. and Weiss, D.: The potentiation of warfarin anticoagulation by amiodarone. Circulation 65: 1025–1029 (1982).PubMedCrossRefGoogle Scholar
  26. Harris, L.; McKenna, W.J.; Krikler, S.J.; Hind, C.R.K.; Savage, C.; Storey, G.C.A. and Holt, D.W.: Renal elimination of amiodarone and its desethyl metabolite. Postgraduate Medical Journal 59: 440–442 (1983b).PubMedCrossRefGoogle Scholar
  27. Harris, L.; McKenna, W.J.; Rowland, E.; Storey, G.C.A.; Krikler, D.M. and Holt, D.W.: Plasma amiodarone and desethyl amiodarone levels in chronic oral therapy. Circulation 64 (Suppl. IV): 263 (1981).Google Scholar
  28. Harris, L.; McKenna, W.J.; Rowland, E.; Holt, D.W.; Storey, G.C.A. and Krikler, D.M.: Side effects of long-term amiodarone therapy. Circulation 67: 45–51 (1983a).PubMedCrossRefGoogle Scholar
  29. Heger, J.J.; Prystowsky, E.N.; Jackman, W.M.; Naccarelli, G.V.; Warfel, K.A.; Rinkenberger, R.L. and Zipes, D.P.: Amiodarone: Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. New England Journal of Medicine 305: 539–545 (1981).PubMedCrossRefGoogle Scholar
  30. Heger, J.J.; Solow, E.B.; Prystowsky, E.N. and Zipes, D.P.: Serum and red cell levels of amiodarone and desethyl amiodarone. Circulation 66 (Suppl. II): 224 (1982).Google Scholar
  31. Heger, J.J.; Prystowsky, E.N. and Zipes, D.P.: Relationship between amiodarone dosage, drug concentrations, and adverse side effets. American Heart Journal 106 (No. 4, Part 2): 931–935 (1983).PubMedCrossRefGoogle Scholar
  32. Holt, P.; Curry, P.; Way, B. and Holt, D.W.: Intravenous amiodarone: An effective anti-arrhythmic agent. American Journal of Cardiology 49: 1001 (1982).CrossRefGoogle Scholar
  33. Holt, D.W.; Tucker, G.T.; Jackson, P.R. and Storey, G.C.A.: Amiodarone pharmacokinetics. American Heart Journal 106: 840–846 (1983).PubMedCrossRefGoogle Scholar
  34. Italian Collaborative Group on Amiodarone: Controlled trial of low dose amiodarone treatment in severe ventricular arrhythmias. American Journal of Cardiology (In press, 1984).Google Scholar
  35. Kannan, R.; Ikeda, N.; Prasad, K.; Kay, I.; Ookhtens, M. and Singh, B.: Plasma kinetics and myocardial disposition of intravenous amiodarone relative to its electrophysiological effects in rabbits and dogs. Circulation 64 (Suppl. IV): 69 (1981).Google Scholar
  36. Kannan, R.; Nademanee, K.; Hendrickson, J.; Rostami, H.J. and Singh, B.N.: Amiodarone kinetics after oral doses. Clinical Pharmacology and Therapeutics 31: 438–444 (1982).PubMedCrossRefGoogle Scholar
  37. Kaski, J.C.; Girotti, L.A.; Messuti, H.; Rutitzky, B. and Rosen-baum, M.B.: Long-term management of sustained, recurrent, symptomatic ventricular tachycardia with amiodarone. Circulation 64: 273–279 (1981).PubMedCrossRefGoogle Scholar
  38. Latini, R.; Connolly, S.; Kernoff, R. and Kates, R.E.: Amiodarone myocardial concentrations correlate better than plasma concentrations with electrophysiologic effects. Circulation 66 (Suppl. II): 223 (1982).Google Scholar
  39. Latini, R.; Connolly, S.J. and Kates, R.E.: Myocardial disposition of amiodarone in the dog. Journal of Pharmacology and Experimental Therapeutics 224: 603–608 (1983).PubMedGoogle Scholar
  40. Latini, R.: Reginato, R.; Bulingame, A.L. and Kates, R.E.: HPLC isolation and FAB-MS identification of di-N-desethylamiodarone, a new metabolite of amiodarone in the dog. Biomedical Mass Speetrometry (In press, 1984).Google Scholar
  41. Lesko, L.J.; Marion, A.; Canada, A.T. and Haffajee, C.: High-pressure liquid chromatography of amiodarone in biological fluids. Journal of Pharmaceutical Sciences 70: 1366–1368 (1981).PubMedCrossRefGoogle Scholar
  42. Lüllmann, H.; Lüllmann-Rauch, R. and Wassermann, O.: Druginduced phospholipidoses. II. CRC Critical Reviews in Toxicology 4: 185–218 (Nov. 1975000).PubMedGoogle Scholar
  43. Lüllmann, H.; Plösch, H. and Ziegler, A.: Ca replacement by cationic amphiphilic drugs from lipid monolayers. Biochemical Pharmacology 29: 2969–2974 (1980).PubMedCrossRefGoogle Scholar
  44. Maggioni, A.P.; Maggi, A.; Volpi, A.; D’Aranno, V.; Tognoni, G. and Giani, P.: Amiodarone distribution in human tissues after sudden death during Holter recording. American Journal of Cardiology 52: 217–218 (1983).PubMedCrossRefGoogle Scholar
  45. Marchiset, D.; Egre, A.; Bailie, Y.; Cano, J.P. and Serradimigni, A.: Taux myocardiques et plasmatiques de l’amiodarone et de son métabolite N-monodéséthylé. Therapie 38: 107–118 (1983).Google Scholar
  46. Marchlinski, F.E.; Gansler, T.S.; Waxman, H.L. and Josephson, M.E.: Amiodarone pulmonary toxicity. Annals of Internal Medicine 97: 839–845 (1982).PubMedGoogle Scholar
  47. Marcus, F.I.: Drug interactions with amiodarone. American Heart Journal 106: 924–929 (1983).PubMedCrossRefGoogle Scholar
  48. Marcus, F.I.; Fontaine, G.H.; Frank, R. and Grosgogeat, Y.: Clinical pharmacology and therapeutic applications of the antiarrhythmic agent, amiodarone. American Heart Journal 101: 480–493 (1981).PubMedCrossRefGoogle Scholar
  49. Martinowitz, U.; Rabinovici, J.; Goldfarb, D.; Many, A. and Bank, H.: Interaction between warfarin sodium and amiodarone. New England Journal of Medicine 304: 671–672 (1981).PubMedCrossRefGoogle Scholar
  50. McKenna, W.J.; Harris, L.; Rowland, E.; Whitelaw, A.; Storey, G. and Holt, D.: Amiodarone therapy during pregnancy. American Journal of Cardiology 51: 1231–1233 (1983).PubMedCrossRefGoogle Scholar
  51. Meier, C.; Kauer, B.; Müller, U. and Ludin, H.P.: Neuromyopathy during chronic amiodarone treatment: A case report. Journal of Neurology 220: 231–239 (1979).PubMedCrossRefGoogle Scholar
  52. Mostow, N.; Rakita, L. and Blumer, J.: Amiodarone: Correlation of serum concentration with clinical efficacy. Circulation 66 (Suppl. II): 223 (1982).Google Scholar
  53. Moysey, J.O.; Jaggarao, N.S.V.; Grundy, E.N. and Chamberlain, D.A.: Amiodarone increases plasma digoxin concentrations. British Medical Journal 282: 272 (1981).PubMedCrossRefGoogle Scholar
  54. Nademanee, K.; Hendrickson, J.; Cannom, D.S.; Goldreyer, B.N. and Singh, B.N.: Control of refractory life-threatening ventricular tachyarrhythmias by amiodarone. American Heart Journal 101: 759–768 (1981).PubMedCrossRefGoogle Scholar
  55. Nademanee, K.; Hendrickson, J.; Kannan, R. and Singh, B.N.: Antiarrhythmic efficacy and electrophysiologic actions of amiodarone in patients with life-threatening ventricular arrhythmias: Potent suppression of spontaneously occurring tachyarrhythmias versus inconsistent abolition of induced ventricular tachycardia. American Heart Journal 103: 950–959 (1982a).PubMedCrossRefGoogle Scholar
  56. Nademanee, K.; Singh, B.N.; Hendrickson, J.; Reed, A.W.; Melmed, S. and Hershman, J.: Pharmacokinetic significance of serum reverse T3 levels during amiodarone treatment: A potential method for monitoring chronic drug therapy. Circulation 66: 202–211 (1982c).PubMedCrossRefGoogle Scholar
  57. Nadenamee, K.; Kannan, R.; Hendrickson, J.; Burnam, M.; Kay, I. and Singh, B.N.: Amiodarone-digoxin interaction during treatment of resistant cardiac arrhythmias. American Journal of Cardiology 49: 1026 (1982b).CrossRefGoogle Scholar
  58. Neyroz, P. and Bonati, M.: In vitro amiodarone protein binding and its interaction with warfarin. Experientia (In press, 1984).Google Scholar
  59. Pitcher, D.; Leather, H.M.; Storey, G.C.A. and Holt, D.W.: Amiodarone in pregnancy. Lancet I: 597–598 (1983).CrossRefGoogle Scholar
  60. Plomp, T.A.; Engles, M.; Robles de Medina, E.O. and Maes, R.A.A.: Simultaneous determination of amiodarone and its major metabolite desethylamiodarone in plasma, urine and tissues by high-performance chromatography. Journal of Chromatography 273: 379–392 (1983).PubMedCrossRefGoogle Scholar
  61. Podrid, P.J. and Lown, B.: Amiodarone therapy in symptomatic sustained refractory atrial and ventricular tachyarrhythmias. American Heart Journal 101: 374–379 (1981).PubMedCrossRefGoogle Scholar
  62. Pritchard, D.A.; Singh, B.N. and Hurley, P.J.: Effects of amiodarone on thyroid function in patients with ischaemia heart disease. British Heart Journal 37: 856–860 (1975).PubMedCrossRefGoogle Scholar
  63. Rakita, L. and Sobol, S.M.: Amiodarone in the treatment of refractory ventricular arrhythmias. Journal of the American Medical Association 250: 1293–1295 (1983).PubMedCrossRefGoogle Scholar
  64. Rees, A.; Dalai, J.J.; Reid, P.G.; Henderson, A.H. and Lewis, M.J.: Dangers of amiodarone and anticoagulant treatment. British Medical Journal 282: 1756–1757 (1981).PubMedCrossRefGoogle Scholar
  65. Richard, C.; Riou, B.; Fournier, C.; Rimailho, A. and Auzepy, P.: Depession of vitamin K-dependent coagulation by amiodarone. Circulation 68 (Suppl. III): A1122 (1983).Google Scholar
  66. Riva, E.; Gerna, M.; Neyroz, P.; Urso, R.; Bartosek, I. and Guaitani, A.: Pharmacokinetics of amiodarone in rats. Journal of Cardiovascular Pharmacology 4: 270–275 (1982a).PubMedCrossRefGoogle Scholar
  67. Riva, E.; Gerna, M.; Latini, R.; Giani, P.; Volpi, A. and Maggioni, A.: Pharmacokinetics of amiodarone in man. Journal of Cardiovascular Pharmacology 4: 264–269 (1982b).PubMedCrossRefGoogle Scholar
  68. Rosenbaum, M.B.; Chiale, P.A.; Halpern, M.S.; Nau, G.J.; Przybylski, J.; Levi, R.J.; Lazzari, J.O. and Elizari, M.V.: Clinical efficacy of amiodarone as an antiarrhythmic agent. American Journal of Cardiology 38: 934–944 (1976).PubMedCrossRefGoogle Scholar
  69. Rosenbaum, M.B.; Chiale, P.A.; Ryba, D. and Elizari, M.V.: Control of tachyarrhythmias associated with Wolff-Parkinson-White syndrome by amiodarone hydrochloride. American Journal of Cardiology 34: 215–223 (1974).PubMedCrossRefGoogle Scholar
  70. Saal, A.K.; Werner, J.A.; Gross, B.W.; Gorham, J.R.; Graham, E.L.; Sears, G.K. and Greene, H.L.: Interaction of amiodarone with quinidine and procainamide. Circulation 66 (Suppl. II): 224 (1982).Google Scholar
  71. Saksena, S.; Rothbart, S.; Kaufmann, W.E. and Rathyen, W.: Chronic electrophysiologic, systemic and pharmacologic effects of amiodarone in recurrent ventricular tachycardia. American Journal of Cardiology 49: 1044 (1982).CrossRefGoogle Scholar
  72. Serlin, M.J.; Sibeon, R.G. and Green, G.J.: Dangers of amiodarone and anticoagulant treatment. British Medical Journal 283: 58 (1981).PubMedCrossRefGoogle Scholar
  73. Siddoway, L.A.; McAllister, C.B.; Wilkinson, G.R.; Roden, D.M. and Woosley, R.L.: Amiodarone dosing: A proposal based on its pharmacokinetics. American Heart Journal 106 (No. 4, part 2): 951–956 (1983).PubMedCrossRefGoogle Scholar
  74. Simpson, W.T.: A review of the therapeutic results and unwanted effects of amiodarone; in Simpson and Caldwell (Eds) Amiodarone in Cardiac Arrhythmias, pp. 45–52 (Academic Press, London 1979).Google Scholar
  75. Singh, B.N.: Amiodarone: Historical development and pharmacologic profile. American Heart Journal 106: 788–797 (1983).PubMedCrossRefGoogle Scholar
  76. Singh, B.N. and Vaughan Williams, E.M.: The effect of amiodarone, a new antianginal drug, on cardiac muscle. British Journal of Pharmacology 39: 657–667 (1970).PubMedCrossRefGoogle Scholar
  77. Singh, B.N.; Jewitt, D.E.; Downey, J.M.; Kirk, E.S. and Sonnenblick, E.H.: Effects of amiodarone and L8040, novel and antianginal and antiarrhythmic drugs on cardiac and coronary haemodynamics and on cardiac intracellular potentials. Clinical and Experimental Pharmacology and Physiology 3: 427–442 (1976).PubMedCrossRefGoogle Scholar
  78. Sobol, S.M. and Rakita, L.: Pneumonitis and pulmonary fibrosis associated with amiodarone treatment: A possible complication of a new antiarrhythmic drug. Circulation 65: 819–824 (1982).PubMedCrossRefGoogle Scholar
  79. Stäubli, M.; Bircher, J.; Galeazzi, R.L.; Remund, H. and Studer, H.: Serum concentrations of amiodarone during long term therapy: Relation to dose, efficacy and toxicity. European Journal of Clinical Pharmacology 24: 485–494 (1983).PubMedCrossRefGoogle Scholar
  80. Storey, G.C.A. and Holt, D.W.: High-performance liquid Chromatographic measurement of amiodarone and desethylamiodarone in plasma or serum at the concentrations attained following a single 400mg dose. Journal of Chromatography 245: 377–380 (1982).PubMedCrossRefGoogle Scholar
  81. Tartini, R.; Kappenberger, L.; Steinbrunn, W. and Meyer, U.A.: Dangerous interaction between amiodarone and quinidine. Lancet 1: 1327–1329 (1982).PubMedCrossRefGoogle Scholar
  82. Touboul, P.; Huerta, F.; Porte, J. and Delahaye, J.P.: Bases électrophysiologiques de l’action antiarythmique de l’amiodarone chez l’homme. Archives des Maladies du Coeur et des Vaisseaux 69: 845–853 (1976).PubMedGoogle Scholar
  83. Vastesaeger, M.; Gillot, P. and Rasson, G.: Étude clinique d’une nouvelle medication antiangoreuse. Acta Cardiologica 22: 483–500 (1967).Google Scholar
  84. Ward, D.E.; Camm, A.J. and Spurrell, R.A.J.: Clinical antiarrhythmic effects of amiodarone in patients with resistant paroxysmal tachycardias. British Heart Journal 44; 91–95 (1980).PubMedCrossRefGoogle Scholar
  85. Waxman, H.L.; Groh, W.C.; Marchlinski, F.E.; Buxton, A.E.; Sadowski, M.; Horowitz, L.N.; Josephson, M.E. and Kastor, J.A.: Amiodarone for control of sustained ventricular tachyarrhythmia: Clinical and electrophysiologic effects in 51 patients. American Journal of Cardiology 50: 1066–1074 (1982)PubMedCrossRefGoogle Scholar
  86. Wellens, H.J.J.; Brugada, P.; Roy, D.; Heddle, B. and Bär, F.W.: A comparison of the electrophysiological effects of intravenous and oral amiodarone. American Journal of Cardiology 49: 1043 (1982).CrossRefGoogle Scholar
  87. Zaher, C; Hamer, A.; Peter, T. and Mandel, W.: Low-dose steroid therapy for prophylaxis of amiodarone-induced pulmonary infiltrates. New England Journal of Medicine 308: 779 (1983).PubMedCrossRefGoogle Scholar

Copyright information

© ADIS Press Limited 1984

Authors and Affiliations

  • Roberto Latini
    • 1
    • 2
  • Gianni Tognoni
    • 1
    • 2
  • Robert E. Kates
    • 1
    • 2
  1. 1.Laboratory of Clinical PharmacologyIstituto di Ricerche Farmacologiche ‘Mario Negri’MilanoItaly
  2. 2.Division of CardiologyStanford University School of MedicineStanfordUSA

Personalised recommendations